NASDAQ:DRMA

Dermata Therapeutics Q2 2026 Earnings Results & Report

Dermata Therapeutics logo
$0.57 -0.03 (-4.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+1.56%)
As of 11/17/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dermata Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.74 versus the -$0.55 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Dermata Therapeutics EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.55
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Dermata Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Dermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Dermata Therapeutics Q2 2026 Earnings FAQ

Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$0.74 per share for Q2 2026, missing the consensus estimate of -$0.55. The report was announced on Tuesday, August 11, 2026.

Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page.

Dermata Therapeutics Earnings Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on Wednesday
See More Dermata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email.

About Dermata Therapeutics

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies.

Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.

View Dermata Therapeutics Profile